CellCentric Employee Directory
Biotechnology ResearchEngland, United Kingdom51-200 Employees
CellCentric is a mid-sized biotechnology company focused on oncology, developing inobrodib, a small-molecule drug that targets the paralogous acetyltransferases p300 and CBP. These gene-activating enzymes are implicated in the progression of certain cancers, and inobrodib is formulated as an oral capsule. The lead candidate is in Phase I/II trials to evaluate its potential against specific solid tumors as well as hematological malignancies. The company operates from Little Chesterford, England, and sits within the biotechnology research sector. By prioritizing cancers with limited treatment options, CellCentric aims to provide new therapeutic options for patients with unmet clinical needs. In 2025, the company expanded its footprint by opening an office in Boston, marking a step in broadening its presence in North America.